Caliper Expects Further $10M-$25M in Divestitures; Eyes IVIS, LabChip Growth | GenomeWeb

NEW YORK (GenomeWeb News) – Caliper Life Sciences expects to divest additional pieces of its business — with total revenues of between $10 million and $25 million — over the next couple of years, President and CEO Kevin Hrusovsky said last week at the JP Morgan Healthcare Conference.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.